You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 獲機構唱好 科濟藥業-B(2171.HK)續升超13%走出反轉行情
格隆匯 08-10 15:58
格隆匯8月10日丨科濟藥業-B(2171.HK)續漲超13%,為連續2日大漲,9個交易日自低位累計漲幅超40%走出反轉行情。現報33.15港元,成交額超1億港元,總市值188億港元。瑞銀首予科濟藥業-B買入評級,目標價49.3港元。該行指,公司的產品料將自2023年起推出市面,估計2023年銷售額將達到2.44億元,考慮到研究投入龐大及前期營銷開支,大概要至2025年才可達到收支平衡,預測CT053及CT041峯值銷售額將達到68億元及59億元。公司已在中國、美國和加拿大獲得7項CAR-T療法的IND許可,在中國所有CAR-T公司中排名第一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account